Technical Analysis for REXN - Rexahn Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 1.67 -2.91% -0.05
REXN closed up 2.38 percent on Tuesday, November 19, 2019, on 11 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical REXN trend table...

Date Alert Name Type % Chg
MACD Bearish Signal Line Cross Bearish -2.91%
1,2,3 Pullback Bullish Bullish Swing Setup -2.91%
Narrow Range Bar Range Contraction -2.91%
NR7 Range Contraction -2.91%
Inside Day Range Contraction -2.91%
Oversold Stochastic Weakness -2.91%
1,2,3 Pullback Bullish Bullish Swing Setup -0.60%
Narrow Range Bar Range Contraction -0.60%
Oversold Stochastic Weakness -0.60%
Fell Below 20 DMA Bearish -4.57%

Older signals for REXN ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Rexahn Pharmaceuticals, Inc. (NYSE American: RNN) is a clinical stage biopharmaceutical company developing innovative therapies to improve patient outcomes in cancers that are difficult to treat. The Company’s mission is to improve the lives of cancer patients by developing next-generation cancer therapies that are designed to maximize efficacy while minimizing the toxicity and side effects traditionally associated with cancer treatment. Rexahn’s product candidates work by targeting and neutralizing specific proteins believed to be involved in the complex biological cascade that leads to cancer cell growth. Preclinical studies show that several of Rexahn’s product candidates may be effective against multiple types of cancer, including drug resistant cancers, difficult-to-treat cancers and others, may augment the effectiveness of current FDA-approved cancer treatments. The Company has two oncology product candidates, RX-3117 and RX-5902, in Phase 2 clinical development and additional compounds in preclinical development, including RX-0301.
Cancer Cancers Cancer Treatment FDA Cancer Therapies Innovative Therapies Next Generation Cancer
Is REXN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 3 bearish and 0 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 19.8
52 Week Low 1.59
Average Volume 62,035
200-Day Moving Average 4.4906
50-Day Moving Average 1.9699
20-Day Moving Average 1.8165
10-Day Moving Average 1.839
Average True Range 0.1775
ADX 32.11
+DI 26.2288
-DI 17.3046
Chandelier Exit (Long, 3 ATRs ) 2.3375
Chandelier Exit (Short, 3 ATRs ) 2.1225
Upper Bollinger Band 2.0728
Lower Bollinger Band 1.5602
Percent B (%b) 0.31
BandWidth 28.219103
MACD Line -0.0576
MACD Signal Line -0.0556
MACD Histogram -0.002
Fundamentals Value
Market Cap 48.95 Million
Num Shares 28.5 Million
EPS -1.01
Price-to-Earnings (P/E) Ratio -1.70
Price-to-Sales 0.00
Price-to-Book 3.65
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.81
Resistance 3 (R3) 1.80 1.76 1.80
Resistance 2 (R2) 1.76 1.74 1.77 1.79
Resistance 1 (R1) 1.74 1.72 1.75 1.75 1.78
Pivot Point 1.70 1.70 1.71 1.71 1.70
Support 1 (S1) 1.68 1.68 1.69 1.69 1.66
Support 2 (S2) 1.64 1.66 1.65 1.65
Support 3 (S3) 1.62 1.64 1.65
Support 4 (S4) 1.63